MYELOPEROXIDASE POLYMORPHISM ON ENDOTHELIAL FUNCTION AND VASCULAR COMPLIANCE

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这项研究的目的是确定一种名为“髓过氧化物酶”的基因的自然变异是否在血管功能异常中起作用。 众所周知，这种血管异常会影响血压，也会导致心脏问题。 这是一项关于髓过氧化物酶（MPO）基因的研究，因为医学研究表明，该基因的某些变化在心脏病患者中更常见。 这是一项关于MPO基因有这种变异的人与没有这种变异的人的血管功能的研究。 这种比较将使用一种名为氨苯砜的药物进行。 已知氨苯砜可阻断MPO基因产生的一种称为“髓过氧化物酶”的酶的作用。 氨苯砜被FDA批准用于治疗某些皮肤病，但被认为是本研究的研究目的。 受试者将1）年龄在18 - 45岁之间，并且没有已知的心脏病风险因素，或2）具有心脏病风险因素，如高血压、高胆固醇或每天吸烟超过1包，持续20年，并且是a）男性，年龄在45-69岁之间，或B）绝经后女性，年龄小于69岁。 受试者将被随机分配接受氨苯砜或安慰剂。 本研究的假设是：1）MPO GG基因型与血管功能受损相关，2）GG基因型受试者的血管功能障碍通过氨苯砜治疗抑制MPO而改善。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this research study is to determine if a natural variation in a gene called "myeloperoxidase" plays a role in the abnormal functioning of blood vessels. It is known that this abnormality of blood vessels affects blood pressure and also leads to heart problems. This is a study of a particular gene, called the myeloperoxidase (MPO) gene, since medical studies have suggested that a certain change in this gene is seen more often in patients with heart disease. This is a study of blood vessel function in people having this variation in the MPO gene compared to a group that does not have the variation. This comparison will be made using a medication called dapsone. Dapsone is known to block the effect of an enzyme called "myeloperoxidase", produced by the MPO gene. Dapsone is approved by the FDA for treatment of certain skin conditions but is considered investigational for the purpose of this study. Subjects will 1) be between 18 and 45 years old and have no known risk factors for heart disaease or 2) have risk factors for heart disease such as high blood pressure, high cholesterol or have smoked more than 1 pack per day for 20 years and are a) male, aged 45-69 years, or b) postmenopausal women, less than 69 years old. Subjects will be randomly assigned to receive dapsone or placebo. The hypotheses of the study are: 1) The MPO GG genotype is associated with impaired vascular function, and 2) vascular dysfunction in subjects with GG genotype is improved by inhibiting MPO with dapsone therapy.